Overview

CDP323 Biomarker Study

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

UCB Pharma

Collaborator:

Biogen